Viridian Therapeutics, Inc.\DE (VRDN) Short term Debt (2014 - 2025)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Short term Debt came in at $8.4 million in Q2 2025, up 184.58% year-on-year from $3.0 million in Q2 2024, and up 184.58% quarter-over-quarter from $3.0 million in Q2 2024.
Viridian Therapeutics, Inc.\DE (VRDN) Short term Debt (2014 - 2025) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Short term Debt history runs 3 years deep, the most recent figure standing at $8.4 million for Q2 2025.
- On a quarterly basis, Short term Debt rose 184.58% year-over-year to $8.4 million in Q2 2025; TTM through Jun 2025 was $8.4 million, a 184.58% increase from a year earlier, with the FY2014 full-year figure at $1.0 million, changed N/A from the prior year.
- Short term Debt advanced to $8.4 million in Q2 2025 per VRDN's latest filing, from $3.0 million in the prior quarter.
- Across five years, Short term Debt topped out at $8.4 million in Q2 2025 and bottomed at $3.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 229.55 Mn | 229.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 8.44 Mn |
| Jun 30, 2024 | 2.96 Mn |
| Dec 31, 2014 | 1.05 Mn |
| Sep 30, 2014 | 1.05 Mn |
| Jun 30, 2014 | 1.05 Mn |